MRNA vs ORLY

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Jul 30, 2026

MRNA

52.3
AI Score
VS
MRNA Wins

ORLY

46.8
AI Score

Investment Advisor Scores

MRNA

52score
Recommendation
HOLD

ORLY

47score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MRNA ORLY Winner
Revenue 389.00M 4.56B ORLY
Net Income -1.34B 604.18M ORLY
Net Margin -345.2% 13.2% ORLY
Operating Income -1.39B 841.61M ORLY
ROE -18.1% -56.6% MRNA
ROA -11.7% 3.6% ORLY
Total Assets 11.49B 16.94B ORLY
Cash 1.91B 252.63M MRNA
Debt/Equity 0.08 -5.81 ORLY
Current Ratio 2.41 0.76 MRNA
Free Cash Flow -692.00M 788.47M ORLY

Relative Price Performance (Last 90 Days)

MRNA 1M: -22.7% · 3M: +21.9% ORLY 1M: +9.9% · 3M: -1.1%

Current Technical Phase

MRNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 50

RSI (14): 50.2 · Price: $59.17

ORLY

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 61

RSI (14): 60.8 · Price: $93.53

Fundamentals Snapshot

Metric MRNA ORLY
Market Cap
Forward P/E -11.0 25.6
Trailing P/E 29.6
Revenue (TTM)
Revenue Growth 0.0% 0.1%
Gross Margin -0.7% 0.5%
Operating Margin -5.6% 0.2%
EPS -7.88 3.15
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, MRNA is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.